Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Conduit Pharmaceuticals Inc. - Common Stock (NQ:CDT)

0.6854 -0.0646 (-8.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Conduit Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Why Cal-Maine Foods Shares Are Trading Higher By 4%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today?
Conduit Pharmaceuticals stock is up on Wednesday alongside heavy trading following an invest update on CDT shares. 
Via InvestorPlace
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
Shares of Rumble Inc. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics
From Conduit Pharmaceuticals
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
What's Going On With Conduit Pharmaceuticals Shares Today?
Conduit Pharmaceuticals Inc. (NASDAQ: CDT) shares are trading higher Thursday after the company announced that the Japan Patent Office granted a composition of matter patent for its lead asset,... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
Approval of composition of matter patent in key jurisdiction underscores the Company’s commitment to maximize future out-licensing value 
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
From Conduit Pharmaceuticals
Via GlobeNewswire
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline
From Conduit Pharmaceuticals
Via GlobeNewswire
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes
From Conduit Pharmaceuticals
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
S&P 500 Moves Higher; BlackRock Reports Upbeat Results
Via Benzinga
Topics Stocks
Exposures US Equities
Gold Gains 1%; Wells Fargo Shares Gain After Q3 Earnings
Via Benzinga
Dow Surges 150 Points; JPMorgan Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Conduit Pharmaceuticals
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we have all of the biggest stories traders need to know about this morning! 
Via InvestorPlace
Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
CDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q2 2024
Conduit Pharmaceuticals just reported results for the second quarter of 2024. 
Via InvestorPlace
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
From Conduit Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.